EMA Authorised: Wyost (denosumab) — Sandoz GmbH

View source ↗

Summary

The European Medicines Agency authorised Wyost, a denosumab medicine from Sandoz GmbH, for Giant Cell Tumor of Bone and related bone neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Neoplasms
• Giant Cell Tumor of Bone

Drugs mentioned

• WYOST (Denosumab)

Snippet

Status: Authorised. Therapeutic area: Giant Cell Tumor of Bone;Neoplasms, Bone Tissue. MAH: Sandoz GmbH. Decision date: 13/08/2025